NCT00002028已完成不适用
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
Bristol-Myers Squibb1 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 1
研究概览
简要总结
The objective of this treatment IND protocol is to make didanosine (ddI) available to patients with HIV infection (suffering from AIDS related complex (ARC) or AIDS) who have developed documented intolerance to zidovudine (AZT) and cannot enter a Phase II ddI program due to protocol exclusion or geographic location.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Concomitant medications for the treatment of AIDS or ARC (including aerosolized pentamidine).
- •Phenytoin, but with caution.
- •Extreme caution should be exercised in the use of ddI in any patient receiving concomitant therapies, particularly those receiving other nucleosides (e.g. ganciclovir), drugs with toxicities similar to those observed with ddI (list included under concomitant medications section of protocol), and other drugs with significant toxicities, including many drugs used for treatment of major opportunistic infections.
- •Patients must:
- •- Have a diagnosis of AIDS or be symptomatic, HIV positive, and have a CD4 cell count < 200 cells/mm
- •Be intolerant to zidovudine (AZT) therapy. Not be suitable for study entry into the phase II didanosine (ddI) study by reason of inclusion or
排除标准
- •or by reason of geographic location.
- •Be able to provide signed informed consent (parent/guardian as appropriate). Be available for monthly follow-up while taking ddI. Meet baseline lab criteria within 14 days prior to initial drug dosing.
- •Extreme caution should be exercised in the use of ddI in any patient receiving concomitant therapies, particularly those receiving other nucleosides (e.g., ganciclovir), drugs with toxicities similar to those observed with ddI (list included under concomitant medications section of protocol), and other drugs with significant toxicities, including many drugs used for treatment of major opportunistic infections.
- •Caution should also be exercised in a patient having intractable diarrhea or patients following a low-sodium diet. Physicians caring for patients must perform clinical and laboratory evaluations every 7 - 10 days for the first 2 months of ddI therapy. All high-risk patients (for example, patients with preexisting disorders of body systems known to be adversely affected by ddI, particularly those with a history of peripheral neuropathy, pancreatitis, seizure disorder, cardiac abnormalities, gout, and significant elevations of liver function test results), must have clinical and laboratory evaluations performed every 10 days and results submitted to Bristol-Myers Squibb on the case report forms provided.
- •Prior Medication:
- •Anti-emetic medication.
- •Required:
- •Zidovudine (AZT).
- •Exclusion Criteria
- •Co-existing Condition:
- •Patients with the following conditions or symptoms are excluded:
- •Malignancy likely to require chemotherapy in the first 3 months of ddI treatment.
- •Acute pancreatitis.
- •A poorly controlled seizure disorder.
- •Grade B or greater peripheral neuropathy.
- •Concurrent Medication:
- •Zidovudine (AZT).
- •Chemotherapy in the first 3 months of ddI treatment.
- •Patients with the following are excluded:
- •Malignancy likely to require systemic chemotherapy in the first 3 months of ddI treatment.
- •Acute pancreatitis.
- •A poorly controlled seizure disorder.
- •Grade B or greater peripheral neuropathy.
- •Prior Medication:
- •Excluded within 15 days of study entry:
- •Any antiretroviral drug except zidovudine (AZT).
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study of ddI in Patients With AIDS Who Become Sicker While Taking ZidovudineLeukoencephalopathy, Progressive MultifocalHIV InfectionsNCT00002274Bristol-Myers Squibb
已完成
1 期
A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant WomenPregnancyHIV InfectionsNCT00000839National Institute of Allergy and Infectious Diseases (NIAID)12
已完成
不适用
Evaluate Initial Safety of the HemiBridge™ System in Guided Spinal Growth Treatment of Progressive Idiopathic ScoliosisScoliosisNCT01465295SpineForm LLC6
已完成
1 期
A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related ComplexHIV InfectionsNCT00000710National Institute of Allergy and Infectious Diseases (NIAID)42
已完成
不适用
Development of Novel Therapies for NIDDMMetabolismNCT01905722Duke University64